Biogen names new chief strategy officer
This article was originally published in Scrip
Biogen Idec, which develops therapies for neurodegenerative diseases, hemophilia and autoimmune disorders, has named Dr Adam Koppel senior vice-president and chief strategy officer – effective 15 May 2014. Dr Koppel will be responsible for leading corporate strategy and portfolio management, as well as ensuring that disease strategies clearly align with the corporate strategy, Biogen said. He will report to chief executive officer Dr George Scangos, and will become a member of Biogen's management team. Prior to joining the Cambridge, Massachusetts-based firm Dr Koppel was managing director of Brookside Capital, the public equity affiliate of Bain Capital.